{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:18:19Z","timestamp":1783358299024,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Postdoctoral Fellowship Program and China Postdoctoral Science Foundation,China","award":["BX20250214"],"award-info":[{"award-number":["BX20250214"]}]},{"name":"Sichuan Science and Technology Program, China","award":["2025ZNSFSC1850"],"award-info":[{"award-number":["2025ZNSFSC1850"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation, China","doi-asserted-by":"crossref","award":["2025T181079"],"award-info":[{"award-number":["2025T181079"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Shengxian Decoction (SXD), a traditional Chinese herbal formula, has demonstrated significant clinical efficacy against lung adenocarcinoma (LUAD). However, its exact mechanisms of action remain to be elucidated. This study aimed to establish an animal model capable of simulating the dynamic progression of LUAD to investigate the anti-tumor effects and immunomodulatory mechanisms of SXD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A TK (\n                      <jats:italic>Trp53<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2212<\/jats:italic>\n                      <\/jats:sup>\n                      ;\n                      <jats:italic>Kras<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>G12D<\/jats:italic>\n                      <\/jats:sup>\n                      ) LUAD mouse model was established by subcutaneously transplanting CRISPR\/Cas9-edited mouse lung organoids into immunocompetent C57BL\/6 mice. The model was characterized by histopathology, RT-qPCR, T7E1 assay, and transcriptomic analysis. Potential mechanisms of SXD were investigated through an integrated approach combining UHPLC-MS\/MS, network pharmacology, molecular docking, and eQTL-based Mendelian randomization. Core targets and key signaling pathways were further evaluated by in vivo transcriptomic analysis, multiplex immunofluorescence, flow cytometry, an in vitro CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell coculture model, and surface plasmon resonance (SPR) analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An immunocompetent TK-LUAD mouse model was successfully established, showing the dynamic pathological progression of LUAD and accompanying changes in immune infiltration. SXD treatment significantly delayed malignant progression in this model and was associated with modulation of the tumor immune microenvironment, as reflected by increased CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration and elevated levels of the cytotoxic effector molecules TNF-\u03b1, IFN-\u03b3, and GZMB. Integrative analyses prioritized\n                      <jats:italic>FYN<\/jats:italic>\n                      as a candidate target potentially involved in SXD-mediated immunomodulation. SPR analysis showed concentration-dependent binding of representative SXD-derived compounds, including secoisolariciresinol, berberine, and acacetin, to\n                      <jats:italic>FYN<\/jats:italic>\n                      , providing additional support for direct target engagement. Further in vivo and in vitro experiments indicated that SXD enhanced the cytotoxic function of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells by activating the FYN-PI3K\/AKT signaling pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study establishes an immunocompetent animal model for investigating LUAD progression and associated changes in the tumor immune microenvironment. In addition, this study provides evidence suggesting that the antitumor activity of SXD may be associated with\n                      <jats:italic>FYN<\/jats:italic>\n                      -related activation of the PI3K\/AKT signaling pathway and subsequent enhancement of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell function. These findings provide a theoretical and experimental basis for further investigation of SXD as a potential therapeutic strategy for LUAD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01442-9","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:28:39Z","timestamp":1783312119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8+ T cell function via the FYN-PI3K\/AKT axis"],"prefix":"10.1186","volume":"21","author":[{"given":"Qiong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"3","key":"1442_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1442_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","volume":"13","author":"G Luo","year":"2025","unstructured":"Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13(4):348\u201363.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1442_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12967-025-06316-6","volume":"23","author":"J Shang","year":"2025","unstructured":"Shang J, Jiang H, Zhao Y, Yang J, Lin Y, Zhang N, et al. Molecular subtyping of stage I lung adenocarcinoma via molecular alterations in pre-invasive lesion progression. J Transl Med. 2025;23(1):263.","journal-title":"J Transl Med"},{"issue":"2","key":"1442_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244\u201385.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1442_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2017161659","volume":"284","author":"H MacMahon","year":"2017","unstructured":"MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228\u201343.","journal-title":"Radiology"},{"issue":"9","key":"1442_CR6","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jtho.2018.05.006","volume":"13","author":"JE Walter","year":"2018","unstructured":"Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, et al. New subsolid pulmonary nodules in lung cancer screening: the NELSON trial. J Thorac Oncol. 2018;13(9):1410\u20134.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"1442_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/abbs\/gmv041","volume":"47","author":"GZ Ge","year":"2015","unstructured":"Ge GZ, Xu TR, Chen C. Tobacco carcinogen NNK-induced lung cancer animal models and associated carcinogenic mechanisms. Acta Biochim Biophys Sin (Shanghai). 2015;47(7):477\u201387.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"7","key":"1442_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41388-023-02929-7","volume":"43","author":"MG Oser","year":"2024","unstructured":"Oser MG, MacPherson D, Oliver TG, Sage J, Park KS. Genetically-engineered mouse models of small cell lung cancer: the next generation. Oncogene. 2024;43(7):457\u201369.","journal-title":"Oncogene"},{"issue":"7","key":"1442_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","volume":"30","author":"HHN Yan","year":"2023","unstructured":"Yan HHN, Chan AS, Lai FP, Leung SY. Organoid cultures for cancer modeling. Cell Stem Cell. 2023;30(7):917\u201337.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1442_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-018-0662-9","volume":"11","author":"H Xu","year":"2018","unstructured":"Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11(1):116.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1442_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13046-025-03385-9","volume":"44","author":"\u0130 Ta\u015f","year":"2025","unstructured":"Ta\u015f \u0130, Jacobs R, Albrecht J, Barrientos SA, \u00c5berg J, Sime W, et al. Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy. J Exp Clin Cancer Res. 2025;44(1):128.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"1442_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1183\/09031936.00124709","volume":"35","author":"S de Seranno","year":"2010","unstructured":"de Seranno S, Meuwissen R. Progress and applications of mouse models for human lung cancer. Eur Respir J. 2010;35(2):426\u201343.","journal-title":"Eur Respir J"},{"issue":"10","key":"1442_CR13","doi-asserted-by":"publisher","first-page":"101777","DOI":"10.1016\/j.xcrm.2024.101777","volume":"5","author":"Y Liu","year":"2024","unstructured":"Liu Y, Lankadasari M, Rosiene J, Johnson KE, Zhou J, Bapat S, et al. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Rep Med. 2024;5(10):101777.","journal-title":"Cell Rep Med"},{"issue":"18","key":"1442_CR14","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"issue":"11","key":"1442_CR15","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/s12276-022-00896-9","volume":"54","author":"J Zhu","year":"2022","unstructured":"Zhu J, Fan Y, Xiong Y, Wang W, Chen J, Xia Y, et al. Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics. Exp Mol Med. 2022;54(11):2060\u201376.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1442_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41467-024-45340-w","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Jiang M, Aye L, Luo L, Zhang Y, Xu F, et al. UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment. Nat Commun. 2024;15(1):1200.","journal-title":"Nat Commun"},{"key":"1442_CR17","doi-asserted-by":"publisher","first-page":"107032","DOI":"10.1016\/j.phrs.2023.107032","volume":"199","author":"R Wang","year":"2024","unstructured":"Wang R, Wang C, Lu L, Yuan F, He F. Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: a comprehensive review with future perspectives. Pharmacol Res. 2024;199:107032.","journal-title":"Pharmacol Res"},{"key":"1442_CR18","doi-asserted-by":"publisher","first-page":"609705","DOI":"10.3389\/fimmu.2020.609705","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lou Y, Wang J, Yu C, Shen W. Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment. Front Immunol. 2021;11:609705.","journal-title":"Front Immunol"},{"key":"1442_CR19","doi-asserted-by":"publisher","first-page":"120250","DOI":"10.1016\/j.jep.2025.120250","volume":"352","author":"S Wang","year":"2025","unstructured":"Wang S, Zhang X, Bai Y, Shi J, Sun Y, Wu H. Shengxian decoction alleviates experimental autoimmune myasthenia gravis by enhancing the immunosuppressive activity of regulatory T cells via Hippo pathway. J Ethnopharmacol. 2025;352:120250.","journal-title":"J Ethnopharmacol"},{"key":"1442_CR20","doi-asserted-by":"publisher","first-page":"1565451","DOI":"10.3389\/fphar.2025.1565451","volume":"16","author":"C Yang","year":"2025","unstructured":"Yang C, Xu Y, Gong F, Li S, Zhan H, Huang Z, et al. Shengxian decoction alleviates cyclophosphamide-induced immunosuppression via improving B cell-mediated immune responses. Front Pharmacol. 2025;16:1565451.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1442_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-025-02245-6","volume":"24","author":"Z Xi","year":"2025","unstructured":"Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H. Traditional Chinese medicine in lung cancer treatment. Mol Cancer. 2025;24(1):57.","journal-title":"Mol Cancer"},{"key":"1442_CR22","doi-asserted-by":"publisher","first-page":"849579","DOI":"10.3389\/fonc.2022.849579","volume":"12","author":"K Li","year":"2022","unstructured":"Li K, You F, Zhang Q, Yuan R, Yuan Q, Fu X, et al. Chemical and biological evidence of the efficacy of Shengxian decoction for treating human lung adenocarcinoma. Front Oncol. 2022;12:849579.","journal-title":"Front Oncol"},{"key":"1442_CR23","doi-asserted-by":"publisher","first-page":"118153","DOI":"10.1016\/j.jep.2024.118153","volume":"329","author":"Y Liang","year":"2024","unstructured":"Liang Y, Yan Y, Liu N, Wang J, Fang C. Shengxian decoction improves lung function in rats with bleomycin-induced idiopathic pulmonary fibrosis through the inhibition of PANoptosis. J Ethnopharmacol. 2024;329:118153.","journal-title":"J Ethnopharmacol"},{"issue":"24","key":"1442_CR24","doi-asserted-by":"publisher","first-page":"e2500019122","DOI":"10.1073\/pnas.2500019122","volume":"122","author":"M Wang","year":"2025","unstructured":"Wang M, Wang Y, Pan X, Wang B, Wang Y, Luo X, et al. Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2025;122(24):e2500019122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1442_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/s42003-024-06755-9","volume":"7","author":"X Qiu","year":"2024","unstructured":"Qiu X, Guo R, Wang Y, Zheng S, Wang B, Gong Y. Mendelian randomization reveals potential causal relationships between cellular senescence-related genes and multiple cancer risks. Commun Biol. 2024;7(1):1069.","journal-title":"Commun Biol"},{"issue":"3","key":"1442_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","volume":"14","author":"Y Yatabe","year":"2019","unstructured":"Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol. 2019;14(3):377\u2013407.","journal-title":"J Thorac Oncol"},{"issue":"48","key":"1442_CR27","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, T-cell development and activation. Oncogene. 2004;23(48):7990\u20138000.","journal-title":"Oncogene"},{"issue":"2","key":"1442_CR28","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.xcrm.2023.100917","volume":"4","author":"L Wu","year":"2023","unstructured":"Wu L, Brzostek J, Sakthi Vale PD, Wei Q, Koh CKT, Ong JXH, et al. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell Rep Med. 2023;4(2):100917.","journal-title":"Cell Rep Med"},{"issue":"Pt 3","key":"1442_CR29","doi-asserted-by":"publisher","first-page":"146486","DOI":"10.1016\/j.ijbiomac.2025.146486","volume":"321","author":"A Ma","year":"2025","unstructured":"Ma A, Yang Z, He Q, Wang W, Ren H, Zhai C, et al. Glyphosate targets FYN to regulate glycolysis and promote glioblastoma proliferation: a network toxicology study. Int J Biol Macromol. 2025;321(Pt 3):146486.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"1442_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s12276-024-01260-9","volume":"56","author":"SH Lim","year":"2024","unstructured":"Lim SH, Lee H, Lee HJ, Kim K, Choi J, Han JM, et al. PLD1 is a key player in cancer stemness and chemoresistance: therapeutic targeting of cross-talk between the PI3K\/Akt and Wnt\/\u03b2-catenin pathways. Exp Mol Med. 2024;56(7):1479\u201387.","journal-title":"Exp Mol Med"},{"key":"1442_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.pathol.3.121806.154244","volume":"6","author":"DJ Cheon","year":"2011","unstructured":"Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011;6:95\u2013119.","journal-title":"Annu Rev Pathol"},{"issue":"24","key":"1442_CR32","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1158\/0008-5472.CAN-15-1249","volume":"75","author":"S Green","year":"2015","unstructured":"Green S, Trejo CL, McMahon M. PIK3CA(H1047R) accelerates and enhances KRAS(G12D)-driven lung tumorigenesis. Cancer Res. 2015;75(24):5378\u201391.","journal-title":"Cancer Res"},{"key":"1442_CR33","doi-asserted-by":"publisher","first-page":"1061388","DOI":"10.3389\/fimmu.2022.1061388","volume":"13","author":"J Yuan","year":"2023","unstructured":"Yuan J, Li X, Yu S. Cancer organoid co-culture model system: novel approach to guide precision medicine. Front Immunol. 2023;13:1061388.","journal-title":"Front Immunol"},{"issue":"1","key":"1442_CR34","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1038\/s41467-024-47547-3","volume":"15","author":"RE Hynds","year":"2024","unstructured":"Hynds RE, Huebner A, Pearce DR, Hill MS, Akarca AU, Moore DA, et al. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models. Nat Commun. 2024;15(1):4653.","journal-title":"Nat Commun"},{"issue":"8","key":"1442_CR35","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/ijc.33713","volume":"149","author":"A Miura","year":"2021","unstructured":"Miura A, Yamada D, Nakamura M, Tomida S, Shimizu D, Jiang Y, et al. Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression. Int J Cancer. 2021;149(8):1593\u2013604.","journal-title":"Int J Cancer"},{"issue":"4","key":"1442_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41389-021-00322-1","volume":"10","author":"S Kato","year":"2021","unstructured":"Kato S, Fushimi K, Yabuki Y, Maru Y, Hasegawa S, Matsuura T, et al. Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. Oncogenesis. 2021;10(4):33.","journal-title":"Oncogenesis"},{"issue":"32","key":"1442_CR37","doi-asserted-by":"publisher","first-page":"e2303134","DOI":"10.1002\/advs.202303134","volume":"10","author":"R Navaridas","year":"2023","unstructured":"Navaridas R, Vidal-Saban\u00e9s M, Ruiz-Mitjana A, Alt\u00e9s G, Perramon-G\u00fcell A, Yeramian A, et al. In vivo intra-uterine delivery of TAT-fused Cre recombinase and CRISPR\/Cas9 editing system in mice unveil histopathology of Pten\/p53-deficient endometrial cancers. Adv Sci (Weinh). 2023;10(32):e2303134.","journal-title":"Adv Sci (Weinh)"},{"key":"1442_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s44178-024-00069-w","volume":"3","author":"J Wang","year":"2024","unstructured":"Wang J, Society of Lung Cancer of China Anti-Cancer A. Caca guidelines for holistic integrative management of lung cancer. Holist Integr Oncol. 2024;3:10.","journal-title":"Holist Integr Oncol"},{"issue":"Pt 2","key":"1442_CR39","doi-asserted-by":"publisher","first-page":"118909","DOI":"10.1016\/j.jep.2024.118909","volume":"337","author":"Y Tang","year":"2025","unstructured":"Tang Y, Wu B, Zhao L, Gao Y, Shen X, Xiao S, et al. Evaluation and the mechanism of ShengXian and JinShuiLiuJun decoction in the treatment of silicotic fibrosis: an integrated network pharmacology, life omics, and experimental validation study. J Ethnopharmacol. 2025;337(Pt 2):118909.","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"1442_CR40","first-page":"6988","volume":"15","author":"R Yuan","year":"2023","unstructured":"Yuan R, Li K, Li Q, Wang C, Zhang H, Ge L, et al. Bioactive components and the molecular mechanism of Shengxian Decoction against lung adenocarcinoma based on network pharmacology and molecular docking. Am J Transl Res. 2023;15(12):6988\u20137012.","journal-title":"Am J Transl Res"},{"issue":"6","key":"1442_CR41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/adt.2023.006","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang Y, Li Z, Jing J, Jiang D, Yuan X, et al. Exploration of the mechanism of Shengxian decoction against chronic obstructive pulmonary disease based on network pharmacology and experimental verification. Assay Drug Dev Technol. 2023;21(6):258\u201372.","journal-title":"Assay Drug Dev Technol"},{"key":"1442_CR42","doi-asserted-by":"publisher","first-page":"737674","DOI":"10.3389\/fphar.2021.737674","volume":"12","author":"F Kong","year":"2021","unstructured":"Kong F, Chen T, Li X, Jia Y. The current application and future prospects of astragalus polysaccharide combined with cancer immunotherapy: a review. Front Pharmacol. 2021;12:737674.","journal-title":"Front Pharmacol"},{"key":"1442_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.molimm.2025.11.010","volume":"188","author":"P Liu","year":"2025","unstructured":"Liu P, Wang S, Bin Y, Xin Z, Yang H, Zhang T, et al. Astragalus polysaccharide promotes CD8 + T cell activity by downregulating Tim-3 to potentiate antitumor immunity. Mol Immunol. 2025;188:121\u201330.","journal-title":"Mol Immunol"},{"issue":"10","key":"1442_CR44","doi-asserted-by":"publisher","first-page":"e146832","DOI":"10.1172\/JCI146832","volume":"131","author":"H Xu","year":"2021","unstructured":"Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest. 2021;131(10):e146832.","journal-title":"J Clin Invest"},{"key":"1442_CR45","doi-asserted-by":"publisher","first-page":"1562248","DOI":"10.3389\/fimmu.2025.1562248","volume":"16","author":"Z Qin","year":"2025","unstructured":"Qin Z, Xu T. Deciphering the deterministic role of TCR signaling in T cell fate determination. Front Immunol. 2025;16:1562248.","journal-title":"Front Immunol"},{"key":"1442_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.suronc.2020.02.002","volume":"33","author":"F Xue","year":"2020","unstructured":"Xue F, Jia Y, Zhao J. Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K\/AKT pathway in lung adenocarcinoma. Surg Oncol. 2020;33:108\u201317.","journal-title":"Surg Oncol"},{"issue":"6","key":"1442_CR47","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/neuonc\/noaa006","volume":"22","author":"A Comba","year":"2020","unstructured":"Comba A, Dunn PJ, Argento AE, Kadiyala P, Ventosa M, Patel P, et al. Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses. Neuro Oncol. 2020;22(6):806\u201318.","journal-title":"Neuro Oncol"},{"key":"1442_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fonc.2018.00235","volume":"8","author":"M Mehrabi","year":"2018","unstructured":"Mehrabi M, Amini F, Mehrabi S. Active role of the necrotic zone in desensitization of hypoxic macrophages and regulation of CSC-fate: a hypothesis. Front Oncol. 2018;8:235.","journal-title":"Front Oncol"},{"issue":"2","key":"1442_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","volume":"24","author":"PDA Vignali","year":"2023","unstructured":"Vignali PDA, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023;24(2):267\u201379.","journal-title":"Nat Immunol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01442-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01442-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01442-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:01:44Z","timestamp":1783357304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01442-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01442-9","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures complied with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of the Hospital of Chengdu University of Traditional Chinese Medicine (Approval No. 2024DL-016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript is approved by all authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}